NCT03741751: CrTMS

Repetitive TMS & Cognitive Training in Adults With Schizophrenia

Terminated NA Results posted Last updated 10 March 2026

What this trial tests

NA trial testing rTMS in Schizophrenia Spectrum and Other Psychotic Disorders in 12 participants. Terminated before completion.

Timeline

15 January 2019

Primary endpoint
31 December 2023

30 January 2024

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	12
Start date	15 January 2019
Primary completion	31 December 2023
Estimated completion	30 January 2024
Sites	1 location across United States

Drugs / interventions tested

• rTMS
• Computerized cognitive training

Conditions studied

• Schizophrenia Spectrum and Other Psychotic Disorders — all drugs for Schizophrenia Spectrum and Other Psychotic Disorders →
• Cognitive Impairment — all drugs for Cognitive Impairment →

Sponsor

Washington University School of Medicine

Who can join

Adults 18 to 65, any sex, with Schizophrenia Spectrum and Other Psychotic Disorders or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in WHODAS Total Score From Baseline to 2 Weeks Secondary · 2 weeks

Disability was measured using the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), a standardized instrument assessing functional impairment across multiple domains of daily living. Total scores range from 0 to 100, with higher scores indicating greater disability. Change scores were calculated as the value at 2 weeks minus the baseline value.

Group	Value	95% CI
Active rTMS With Computerized Cognitive Training	-1.33	± 2.31
Sham rTMS With Computerized Cognitive Training	-10.33	± 11.50

Difference in Groups on Neuropsychological Testing Primary · 2 weeks

Evaluate differences in neuropsychological functioning between active and sham rTMS groups using the Screen for Cognitive Impairment in Psychiatry (SCIP). Scores are reported as Z-scores standardized to age-adjusted normative data. A Z-score of 0 represents the population mean, and each unit reflects one standard deviation from that mean. Higher Z-scores indicate better cognitive performance. Scores are interpreted relative to normative expectations rather than a diagnostic threshold. Change scores represent the value at 2 weeks minus the baseline value.

Group	Value	95% CI
Active rTMS With Computerized Cognitive Training	1.89	± 1.67
Sham rTMS With Computerized Cognitive Training	0.48	± 1.01

Adverse events — posted to ClinicalTrials.gov

Time frame: From enrollment until the end of participation, up to 2 weeks.. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Active rTMS With Computerized Cognitive Training

Serious: 0/3 (0%)

Deaths: 0/3

Sham rTMS With Computerized Cognitive Training

Serious: 0/3 (0%)

Deaths: 0/3

Other adverse events (1 terms — click to expand)

Reaction	System	Active rTMS With Computeri…	Sham rTMS With Computerize…
headache	Nervous system disorders	—	—

Data from ClinicalTrials.gov NCT03741751 adverse events section.

Sponsor's own description

The proposed project aims to establish the feasibility and tolerability of delivering repetitive transcranial magnetic stimulant (rTMS) combined with computerized cognitive training in patients with Schizophrenia or Schizoaffective Disorder and cognitive difficulties.

The investigators will conduct a 2 week randomized controlled trial study evaluating computerized cognitive training combined with either active or sham rTMS on cognitive and functional outcomes in adults with Schizophrenia or Schizoaffective Disorder.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.